Clinical and Laboratory Improvement in Hyperadrenergic Postural Orthostatic Tachycardia Syndrome (POTS) after COVID-19 Infection

A 32-year-old woman with a history of symptomatic supraventricular tachycardia, inappropriate sinus tachycardia, and hyperadrenergic POTS was treated with ivabradine and metoprolol. She then presented with bradycardia and Mobitz II second-degree AV block on event monitoring six weeks after COVID-19 infection. Her post-viral workup revealed normalization of catecholamine levels and significant symptomatic improvement in heart rate. To the authors' knowledge, this is the first reported case of improvement in POTS after COVID-19 infection. As our understanding of COVID-19 continues to improve, it will be vital to better understand the impact of COVID-19 dysautonomia on cardiac patients.

[1]  P. Taub,et al.  Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. , 2021, Journal of the American College of Cardiology.

[2]  P. Brodin.  Immune determinants of COVID-19 disease presentation and severity , 2021, Nature Medicine.

[3]  R. Sutton,et al.  Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. , 2020, Clinical medicine (London).

[4]  B. Grubb,et al.  New-onset Postural Orthostatic Tachycardia Syndrome Following Coronavirus Disease 2019 Infection , 2020, The Journal of innovations in cardiac rhythm management.

[5]  A. Tanuri,et al.  Current evidence of neurological features, diagnosis, and neuropathogenesis associated with COVID-19 , 2020, Revista da Sociedade Brasileira de Medicina Tropical.

[6]  K. Nugent,et al.  Dysautonomia: An Overlooked Neurological Manifestation in a Critically ill COVID-19 Patient , 2020, The American Journal of the Medical Sciences.

[7]  C. Stecco,et al.  Sympathetic activation: a potential link between comorbidities and COVID‐19 , 2020, The FEBS journal.

[8]  B. Levine,et al.  Postural Orthostatic Tachycardia Syndrome: JACC Focus Seminar. , 2019, Journal of the American College of Cardiology.

[9]  P. Taub,et al.  Postural Orthostatic Tachycardia Syndrome: Prevalence, Pathophysiology, and Management , 2018, Drugs.

[10]  A. Abdulla,et al.  Reversible postural orthostatic tachycardia syndrome. , 2015, World journal of clinical cases.

[11]  U. Graham,et al.  Postural orthostatic tachycardia syndrome , 2009, BMJ Case Reports.